Literature DB >> 1733777

Shortened cecropin A-melittin hybrids. Significant size reduction retains potent antibiotic activity.

D Andreu1, J Ubach, A Boman, B Wåhlin, D Wade, R B Merrifield, H G Boman.   

Abstract

We have earlier reported two 26-residue antibacterial peptides made up from different segments of cecropin A (CA) and melittin (M). We now report a substantial reduction in size at the C-terminal section of the highly active hybrid CA(1-8)M(1-18), leading to a series of 20-, 18- and 15-residue analogs with antibiotic properties similar to the larger molecule. In particular, the 15-residue hybrids CA(1-7)M(2-9), CA(1-7)M(4-11) and CA(1-7)M(5-12) are the shortest cecropin-based peptide antibiotics described so far, with antibacterial activity and spectra similar or better than cecropin A and a 60% reduction in size. Their reduced size and highly alpha-helical structure require an alternative mechanism for their interaction with bacterial membranes.

Mesh:

Substances:

Year:  1992        PMID: 1733777     DOI: 10.1016/0014-5793(92)80377-s

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  67 in total

1.  Activities of synthetic hybrid peptides against anaerobic bacteria: aspects of methodology and stability.

Authors:  H Oh; M Hedberg; D Wade; C Edlund
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  N-terminal fatty acid substitution increases the leishmanicidal activity of CA(1-7)M(2-9), a cecropin-melittin hybrid peptide.

Authors:  C Chicharro; C Granata; R Lozano; D Andreu; L Rivas
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 3.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects.

Authors:  Amy A Baxter; Fung T Lay; Ivan K H Poon; Marc Kvansakul; Mark D Hulett
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

4.  Membrane binding, structure, and localization of cecropin-mellitin hybrid peptides: a site-directed spin-labeling study.

Authors:  Kalpana Bhargava; Jimmy B Feix
Journal:  Biophys J       Date:  2004-01       Impact factor: 4.033

5.  Change of glutamic acid to lysine in a 13-residue antibacterial and hemolytic peptide results in enhanced antibacterial activity without increase in hemolytic activity.

Authors:  N Sitaram; M Chandy; V N Pillai; R Nagaraj
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

6.  Comparison of in vitro antibacterial activities of two cationic peptides CM15 and CM11 against five pathogenic bacteria: Pseudomonas aeruginosa, Staphylococcus aureus, Vibrio cholerae, Acinetobacter baumannii, and Escherichia coli.

Authors:  M Moosazadeh Moghaddam; F Abolhassani; H Babavalian; R Mirnejad; K Azizi Barjini; J Amani
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

7.  Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index.

Authors:  Yuxin Chen; Colin T Mant; Susan W Farmer; Robert E W Hancock; Michael L Vasil; Robert S Hodges
Journal:  J Biol Chem       Date:  2005-01-27       Impact factor: 5.157

8.  Investigation of the antibacterial activity of a short cationic peptide against multidrug-resistant Klebsiella pneumoniae and Salmonella typhimurium strains and its cytotoxicity on eukaryotic cells.

Authors:  Mehrdad Moosazadeh Moghaddam; Kamal Azizi Barjini; Mahdi Fasihi Ramandi; Jafar Amani
Journal:  World J Microbiol Biotechnol       Date:  2013-12-10       Impact factor: 3.312

9.  Design and high-level expression of a hybrid antimicrobial peptide LF15-CA8 in Escherichia coli.

Authors:  Xing-Jun Feng; Li-Wei Xing; Di Liu; Xue-Ying Song; Chun-Long Liu; Jing Li; Wen-Shan Xu; Zhong-Qiu Li
Journal:  J Ind Microbiol Biotechnol       Date:  2013-11-27       Impact factor: 3.346

10.  Lysine-enriched cecropin-mellitin antimicrobial peptides with enhanced selectivity.

Authors:  Hiromi Sato; Jimmy B Feix
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.